Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.lungcan.2025.108477 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reassessing pembrolizumab dosing in NSCLC for methodological and clinical accuracy - Author's reply.
Lung Cancer
March 2025
Department of Pharmacy, Rode Kruis Ziekenhuis, Beverwijk, The Netherlands.
The KEYNOTE-564 trial showed that adjuvant immune checkpoint inhibitor (ICI) therapy with pembrolizumab, a PD-1 antibody, significantly improved disease-free survival (DFS) and overall (OS) survival in localised clear-cell renal cell carcinoma (RCC) with a high risk of relapse. The TiNivo and CONTACT-03 trials have reported results for subsequent therapy after progression on ICI therapy in the metastatic setting. The European Association of Urology (EAU) RCC guidelines panel reassessed the new trial results to update recommendations for adjuvant therapy and post-adjuvant therapy.
View Article and Find Full Text PDFBackground: Immunotherapy is one of the fundamental treatment modalities, especially in the treatment of metastatic non-small cell lung carcinoma, but it is also applied in neoadjuvant, or adjuvant therapy. A certain limitation continues to be immune-mediated toxicity and the broad clinical spectrum of its manifestations, which can present considerable differential diagnostic challenges.
Case: We present a case of a female patient who has been treated at our institute since February 2023 for metastatic squamous cell carcinoma of the right lung with first-line systemic therapy of pembrolizumab in initial combination with carboplatin and paclitaxel.
Reassessing pembrolizumab dosing in NSCLC for methodological and clinical accuracy.
Lung Cancer
November 2024
Clinical Science Institute, University Hospital Galway, University of Galway, Galway, Ireland. Electronic address:
2024 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma.
Expert Rev Anticancer Ther
August 2024
Medical Oncology, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
In this article, we report the breakthrough acquisitions for renal cell carcinoma (RCC) management presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. The results from Keynote 564 showed an impressive overall survival (OS) advantage for pembrolizumab, in patients at higher risk of relapse after surgery and confirmed the benefit in terms of disease-free survival (DFS). Until now, pembrolizumab is the only immune checkpoint inhibitor (ICI) to prove a survival advantage.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!